Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges
Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales
Up to $113 million of potential milestone payments in the discovery phase, with $20 million upfront at initiation for three projects
https://finance.yahoo.com/news/exscientia-announces-ai-drug-discovery-050000497.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.